TAN-67 dihydrobromide

Research use only, not for human use.

A potent and selective δ-opioid receptor agonist that has high affinity and selectivity for the δ1 subtype with Ki of 1.12 nM.

A potent and selective δ-opioid receptor agonist that has high affinity and selectivity for the δ1 subtype with Ki of 1.12 nM; dispalys >1,000-fold selectivity over μOR and κOR; Pain Discontinued.

——

Animal Model: Adult C57BL/6J male mice with I/R-caused brain injury Dosage:1.5, 3.0, and 4.5 mg/kg Administration:Intravenous injection; onceResult:Reduced infarct volume in a dose-dependent manner.Animal Model:Adult C57BL/6J male mice with I/R-caused brain injury Dosage:3.0 mg/kg Administration:Intravenous injection; once Result:Had rapidly functional recovery than the vehicle-treated mice.Reduced neuronal cell death.Animal Model:Adult C57BL/6J male mice with transient middle cerebra artery occlusion (MCAO) ischemic stroke modelDosage:3.0 mg/kg Administration:Intravenous injection; once Result:Increased both total APP and mature APP (APPm) levels.Reduced β-secretase activity.

SB 205607

Endocrinology/Hormones

Opioid Receptor

Opioid Receptor

Neurological Disease

Pain

1217628-73-3

506.28

C23H24N2O.2HBr

>98% (HPLC)

——

CN1C[C@@H]2CC3=CC4=CC=CC=C4N=C3C[C@@]2(C5=CC=CC(O)=C5)CC1.[H]Br.[H]Br

3-((4aS,12aR)-2-methyl-1,3,4,5,12,12a-hexahydropyrido[3,4-b]acridin-4a(2H)-yl)phenol dihydrobromide

(-20℃)

With Ice Pack

≥ 2 years